JP2024506145A - 半減期延長部分及びその使用方法 - Google Patents

半減期延長部分及びその使用方法 Download PDF

Info

Publication number
JP2024506145A
JP2024506145A JP2023546450A JP2023546450A JP2024506145A JP 2024506145 A JP2024506145 A JP 2024506145A JP 2023546450 A JP2023546450 A JP 2023546450A JP 2023546450 A JP2023546450 A JP 2023546450A JP 2024506145 A JP2024506145 A JP 2024506145A
Authority
JP
Japan
Prior art keywords
seq
sequence
compound
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506145A5 (cg-RX-API-DMAC10.html
Inventor
フェランテ，アンドレア
ジョージ ヒューアー，ジョゼフ
リン リー，ステイシー
ヴェルディーノ，ペトラ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024506145A publication Critical patent/JP2024506145A/ja
Publication of JP2024506145A5 publication Critical patent/JP2024506145A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023546450A 2021-02-02 2022-02-01 半減期延長部分及びその使用方法 Pending JP2024506145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144696P 2021-02-02 2021-02-02
US63/144,696 2021-02-02
PCT/US2022/014728 WO2022169757A1 (en) 2021-02-02 2022-02-01 Half-life extending moieties and methods of using the same

Publications (2)

Publication Number Publication Date
JP2024506145A true JP2024506145A (ja) 2024-02-09
JP2024506145A5 JP2024506145A5 (cg-RX-API-DMAC10.html) 2025-02-10

Family

ID=80735776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546450A Pending JP2024506145A (ja) 2021-02-02 2022-02-01 半減期延長部分及びその使用方法

Country Status (18)

Country Link
US (1) US20240316154A1 (cg-RX-API-DMAC10.html)
EP (1) EP4288452A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024506145A (cg-RX-API-DMAC10.html)
KR (1) KR20230137342A (cg-RX-API-DMAC10.html)
CN (1) CN116802209A (cg-RX-API-DMAC10.html)
AU (1) AU2022217754A1 (cg-RX-API-DMAC10.html)
CA (1) CA3204225A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023002285A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023010002A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230366A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000149A (cg-RX-API-DMAC10.html)
EC (1) ECSP23058246A (cg-RX-API-DMAC10.html)
IL (1) IL304219A (cg-RX-API-DMAC10.html)
JO (1) JOP20230173A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009006A (cg-RX-API-DMAC10.html)
PE (1) PE20240233A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022169757A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202306754B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260109751A1 (en) * 2022-12-30 2026-04-23 Eli Lilly And Company Methods of dulaglutide purification using hydrophobic interaction chromatography
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517561A (ja) * 2008-03-31 2011-06-16 グラクソ グループ リミテッド 薬物融合体および複合体
JP2014522641A (ja) * 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
JP2017512469A (ja) * 2014-03-20 2017-05-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
JP2020511113A (ja) * 2016-12-07 2020-04-16 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
JP7270105B2 (ja) * 2019-07-31 2023-05-09 イーライ リリー アンド カンパニー インスリン類似体およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517561A (ja) * 2008-03-31 2011-06-16 グラクソ グループ リミテッド 薬物融合体および複合体
JP2014522641A (ja) * 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
JP2017512469A (ja) * 2014-03-20 2017-05-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
JP2020511113A (ja) * 2016-12-07 2020-04-16 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
JP7270105B2 (ja) * 2019-07-31 2023-05-09 イーライ リリー アンド カンパニー インスリン類似体およびその使用方法
JP7748358B2 (ja) * 2019-07-31 2025-10-02 イーライ リリー アンド カンパニー リラキシン類似体およびその使用方法

Also Published As

Publication number Publication date
PE20240233A1 (es) 2024-02-16
ECSP23058246A (es) 2023-09-29
CO2023010002A2 (es) 2023-09-08
KR20230137342A (ko) 2023-10-04
CR20230366A (es) 2023-10-03
CN116802209A (zh) 2023-09-22
ZA202306754B (en) 2025-02-26
JOP20230173A1 (ar) 2023-07-30
CL2023002285A1 (es) 2024-02-23
AU2022217754A1 (en) 2023-07-27
DOP2023000149A (es) 2023-09-15
CA3204225A1 (en) 2022-08-11
EP4288452A1 (en) 2023-12-13
WO2022169757A1 (en) 2022-08-11
MX2023009006A (es) 2023-08-08
CL2025003008A1 (es) 2025-12-19
US20240316154A1 (en) 2024-09-26
IL304219A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP7270105B2 (ja) インスリン類似体およびその使用方法
US11813315B2 (en) Fibronectin based scaffold domain proteins that bind to myostatin
JP7064618B2 (ja) 増殖分化因子１５アゴニスト化合物およびその使用方法
CN113166218B (zh) 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
KR20230137342A (ko) 반감기 연장 모이어티 및 그의 사용 방법
EA048693B1 (ru) Фрагменты, увеличивающие период полужизни, и способы их применения
EA046279B1 (ru) Аналоги релаксина и способы их использования
EA042599B1 (ru) Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения
HK40042173A (en) Growth differentiation factor 15 agonist compounds and methods of using the same
HK1212717B (en) Fibronectin based scaffold domain proteins that bind to myostatin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260702